Triglycerides: ranges, results and what changes them

These are common adult fasting categories. A laboratory can use a different flag, and children, pregnancy, known lipid disorders and clinician-managed treatment use different context. The mmol/L boundaries are exact conversions of the mg/dL cutoffs; classify from the original result and unit rather than moving a rounded conversion across a boundary.^{See reference 3,See reference 4,See reference 6}

For nonfasting samples, ACC guidance uses 175 mg/dL (1.9758 mmol/L) or above as an elevation and action threshold. The term persistent should not be assigned from one nonfasting result. A value below 175 is not automatically optimal for every person, and one value above it does not prove disease.^{See reference 1,See reference 2,See reference 5,See reference 6}

Clinical priorities change at severe levels. At 500 mg/dL and above, preventing pancreatitis becomes an explicit part of management; around and above 1,000 mg/dL, chylomicrons and genetic or multifactorial chylomicronemia need particular consideration.^{See reference 2,See reference 7,See reference 8}

Triglycerides are the main form in which the body carries and stores fat. After a meal, dietary triglycerides travel mainly in chylomicrons. The liver also packages triglycerides into very-low-density lipoproteins (VLDL). A standard blood test reports the total triglyceride concentration across these circulating particles; it does not count them or identify one source.^{See reference 2,See reference 3,See reference 13}

The result cannot show artery plaque, diagnose pancreatitis, prove insulin resistance or reveal whether a cause is genetic. It becomes more useful when read with the sampling state, prior results, non-HDL cholesterol or ApoB, glucose-related markers, thyroid function, liver and kidney context, medicines, alcohol intake and symptoms.^{See reference 1,See reference 2,See reference 4,See reference 8}

For triglycerides, multiply mg/dL by 0.01129 to obtain mmol/L. The practical inverse is to multiply mmol/L by 88.57 to obtain mg/dL. This factor is specific to triglycerides; cholesterol uses a different factor because the molecules have different mass.^{See reference 6}

The calculators round only the displayed answer. Near a category boundary, use the laboratory's original value and unit. For example, 150 mg/dL converts to 1.6935 mmol/L, commonly displayed as 1.69, and 500 mg/dL converts to 5.6450 mmol/L, commonly displayed as 5.65.^{See reference 3,See reference 6}

Common contributors include excess energy intake, alcohol, high-glycaemic or high-fructose patterns, overweight or visceral fat, low physical activity, insulin resistance and poorly controlled diabetes. A recent meal can contribute to a nonfasting result, but it should not automatically be blamed for a markedly high value.^{See reference 2,See reference 4,See reference 5}

Medical and treatment-related contributors include hypothyroidism, chronic kidney disease, some liver conditions, pregnancy, inflammatory illness and several medicines. Genetics can range from common susceptibility interacting with lifestyle and health conditions to rare familial chylomicronemia syndrome.^{See reference 2,See reference 4,See reference 7,See reference 8}

The pattern matters. High triglycerides with low HDL-C, raised glucose or HbA1c, central weight gain or fatty-liver context can point toward metabolic drivers. When triglycerides are elevated, raised non-HDL cholesterol means more cholesterol is carried across apoB-containing particles, while raised ApoB points to more atherogenic particles. These measures are related but not interchangeable, and the patterns do not diagnose a condition by themselves.^{See reference 1,See reference 2,See reference 13}

Common adult triglyceride tables define categories for increasing values but do not set a lower disease threshold. An isolated low result is therefore not a diagnosis and is often interpreted as part of the wider lipid and health picture.^{See reference 3,See reference 4}

If a value is unexpectedly low or falling alongside weight loss, digestive symptoms, poor intake, thyroid symptoms or other illness, discuss the pattern rather than trying to raise triglycerides from a generic range. Compare the same unit and similar sampling conditions first.^{See reference 3,See reference 6,See reference 12}

Non-HDL cholesterol and ApoB help describe the cholesterol content or number of atherogenic particles when triglycerides are elevated. LDL-C still matters, but some LDL calculations become less reliable as triglycerides rise, so the method and the rest of the lipid panel deserve attention.^{See reference 1,See reference 2,See reference 13}

HDL-C, fasting glucose, HbA1c, thyroid-stimulating hormone, liver enzymes and kidney measures can help expose a pattern or secondary cause. The triglyceride-to-HDL ratio is studied as an indirect marker, but its predictive performance and thresholds vary by population, sex and ethnicity. It should not be used alone to diagnose insulin resistance or replace validated risk assessment.^{See reference 2,See reference 4,See reference 16}

At severe levels, the immediate aim includes lowering pancreatitis risk. At lower persistent elevations, the plan focuses more on secondary causes, overall cardiovascular risk and proven risk-reducing treatment. Statins may be central to cardiovascular prevention even when a reader thinks of them as cholesterol medicines rather than triglyceride medicines.^{See reference 1,See reference 2,See reference 7}

Trials show why the exact therapy matters. In PROMINENT, pemafibrate lowered triglycerides in adults with diabetes but did not reduce the primary cardiovascular outcome. In REDUCE-IT, purified prescription icosapent ethyl reduced cardiovascular events in a selected high-risk, statin-treated population. Neither result supports self-treatment or assuming that every triglyceride-lowering product has the same benefit.^{See reference 14,See reference 15}

Prescription omega-3 medicines also differ from supplements in dose, purity, regulation and evidence. A clinician should consider bleeding risk, atrial fibrillation, interactions, kidney or liver disease and pregnancy before choosing treatment.^{See reference 1,See reference 10,See reference 15}

Repeat timing depends on why the test was done and whether the result will change a decision. Current U.S. guidance defines persistent hypertriglyceridemia only after an appropriate period of lifestyle and secondary-cause management, and it uses at least two fasting measurements at least two weeks apart for selected non-statin treatment decisions.^{See reference 1,See reference 2}

A fasting repeat can be useful after a very high nonfasting result, when pancreatitis risk or a triglyceride disorder is being assessed, or when triglycerides affect LDL calculation. Use the same unit, note fasting duration, recent alcohol, illness and medicine changes, and do not postpone timely review of a severe result merely to collect a cleaner number.^{See reference 1,See reference 2,See reference 5,See reference 12}